Dr. Jiong-Wei Wang obtained his PhD degree in Medicine from the Leiden University Medical Centre, The Netherlands, in 2013. After post-doctoral training at University Medical Center (UMC) Utrecht (The Netherlands) and National University of Singapore, he started his faculty position as an Assistant Professor in July 2019 at the National University of Singapore. Besides Department of Surgery, he holds a joint appointment at the Department of Physiology for teaching. For research, he is a Principal Investigator at the Cardiovascular Research Institute (CVRI; National University Heart Centre Singapore) and the Nanomedicine Translational Research Program (Yong Loo Lin School of Medicine). His research has been supported by National Medical Research Council (NMRC), Ministry of Education (MOE) and NUS/NUHS among others. He was awarded three times the “Young Investigator Award” by the International Society on Thrombosis and Haemostasis (ISTH), twice travel awards by the European Society of Cardiology (ESC), and the Outstanding Mentor Award in 2019 by Wong Hock Boon Society–Singapore Medical Association (SMA) Charity Fund (WHBS-SMACF). For service, Dr. Wang is currently the Chairperson for Department Safety & Health and a committee member for Safety & Health at Yong Loo Lin School of Medicine.

 

Education

• Ph.D. in Medicine, Leiden University Medical Centre, The Netherlands
• M.Sc. in Cell Biology and Biophysics, Beijing Normal University & Institute of Biophysics (CAS), China
• B.Sc. in Life Sciences, Henan Normal University, China
• Postdoctoral Research Fellow (Cardiovascular research), National University of Singapore
• Postdoctoral Research Fellow (Experimental Cardiology), University Medical Centre Utrecht, The Netherlands

Professional service and membership

• Member of European Society of Cardiology
• Editorial board member for Frontiers in Cardiovascular Medicine, Heliyon, International Journal of Drug Discovery and Pharmacology, Journal of Laboratory and Precision Medicine; invited guest editor for Frontiers in Immunology, Biology, among others.
• Reviewer for funding bodies (grants) and prestigious scientific journals, including Advanced Drug Delivery Reviews, Small, Theronostics, Matter, Journal of Extracellular Vesicles, Cardiovascular Research, Journal of Controlled Release, among others.

Research Interest and Activities
Dr Wang has been working on cardio-metabolic diseases, cardiac immunology, extracellular vesicles and nanomedicine. His laboratory has established various preclinical animal models of human diseases, including heart failure and injury (myocardial infarction, ischemia reperfusion injury, pressure overload, diet-induced heart failure), atherosclerosis, and non-alcoholic fatty liver disease. Together with several senior colleagues, he initiated and has been leading a NanoNASH research program that aims to develop and translate nanomedicine-based diagnosis and therapies for the treatment of fatty liver disease. Within the Centre for NanoMedicine and Nanomedicine TRP, his group also works on new nanomaterials and drug delivery systems (carrying small molecules, nucleic acids, RNAs etc) for translational research in cardiovascular disease, fatty liver disease and gut related disease.

Recent Publications (selection of total > 70 articles, detailed information referred to https://scholar.google.com/citations?user=HnUqhCMAAAAJ&hl=en or https://www.researchgate.net/profile/Jiong-Wei-Wang or https://orcid.org/0000-0001-7986-6082) 

1. Yu XD, Wang JW. Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives. Biochem Pharmacol. 2022 Aug;202:115157. doi: 10.1016/j.bcp.2022.115157. Epub 2022 Jun 28.
2. Lau CYJ, Benne N, Lou B, Zharkova O, Ting HJ, Ter Braake D, van Kronenburg N, Fens MH, Broere F, Hennink WE, Wang JW*, Mastrobattista E*. Modulating albumin-mediated transport of peptide-drug conjugates for antigen-specific Treg induction. J Control Release. 2022 Aug;348:938-950. doi: 10.1016/j.jconrel.2022.06.025.
3. Zhang Z#, Dalan R#, Hu Z#, Wang JW#, Chew NW, Poh KK, Tan RS, Soong TW, Dai Y, Ye L*, Chen X*. Reactive Oxygen Species Scavenging Nanomedicine for The Treatment of Ischemic Heart Disease. Adv Mater. 2022 Sep;34(35):e2202169. doi: 10.1002/adma.202202169.